Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
about
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicChaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions.Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsThe possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignanciesHeat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.Panobinostat for the treatment of acute myelogenous leukemia.C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemiaS100 Proteins in Acute Myeloid Leukemia
P2860
Q26751011-BB6A37C1-F13B-4E8F-950E-D0E3CDD0E327Q34817365-9C5330D0-63D8-48C5-82C6-5920723B33C2Q36744579-D6EC3AC1-76BC-4748-866A-B3AC5D041742Q37000704-650FD3F0-7F34-4FDB-B883-B04861976F1BQ37132224-9279D927-C1D7-43C2-80FC-5FD4DA845499Q38083604-AFAF9826-5833-4CEF-8962-3409BC2D6C28Q38166527-E8A8501A-82E8-49E4-89AB-753C4E09C0F7Q38222563-F3447787-92D5-473C-BEBE-0AAAAE7520A8Q38401664-1B0A3F37-7C3E-4323-B641-A34B3A8C266FQ38435352-59F01FEC-6D2D-4774-81AB-9D583168A756Q38740513-8329C63A-6FE2-493B-8EE6-73CCF6E0084FQ38835113-E94C1ACE-B4E3-4C4E-BF19-CE31D354A9F4Q38906493-A92DC06C-9912-42AE-B982-D4E7D67E211CQ38989476-DCBFAE71-2FE3-486B-81B3-5A82BB6E844AQ41965978-85023D42-8D5F-4358-9DE9-95ECFF1C0364Q43461214-BA62F0E0-2783-4620-AC9E-3BACB2D85E99Q46516275-C8B323F8-0A62-499D-9412-8AC058B3510DQ46614261-AE4A2309-1B50-452F-A13C-9957300AEBE7Q51068076-5CA038F7-1CEA-4173-A2BE-F02FEB0F0C58Q52846906-E7471065-5888-4B21-BA77-5960D400E848Q57821075-BB9303E9-81D8-42B8-93FE-65B471A9F677Q58576722-9D7317B9-CBC2-4128-8EEA-CE4F5CF5ECAF
P2860
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Expression profile of heat sho ...... pharmacological intervention.
@en
Expression profile of heat sho ...... pharmacological intervention.
@nl
type
label
Expression profile of heat sho ...... pharmacological intervention.
@en
Expression profile of heat sho ...... pharmacological intervention.
@nl
prefLabel
Expression profile of heat sho ...... pharmacological intervention.
@en
Expression profile of heat sho ...... pharmacological intervention.
@nl
P2093
P2860
P1476
Expression profile of heat sho ...... pharmacological intervention.
@en
P2093
Elisabeth Ersvaer
Håkon Reikvam
Jørn Skavland
Kimberley J Hatfield
Kjell Petersen
Oystein Bruserud
Randi Hovland
P2860
P304
P356
10.1111/J.1365-2141.2011.08960.X
P407
P577
2011-12-13T00:00:00Z